OJOG  Vol.1 No.3 , September 2011
Prognostic factors for survival after neoadjuvant chemotherapy for advanced ovarian cancer: meta-analysis
Background: In advanced disease current practice is staging and primary debulking laparotomy followed by platinum-based chemotherapy. The effort to achieve ‘optimal debulking’ is associated with a complication risk of 8% - 63% and a mortality rate of 1% - 6%. Neoadjuvant chemotherapy has been proposed as an alternative option. Objectives: This meta-analysis aimed to determine prognostic factors influencing survival in patients with advanced ovarian cancer following neoadjuvant chemotherapy. Search Strategy: Clinical trials citing the terms ‘advanced ovarian cancer’, ‘ovarian cancer’, ‘neoadjuvant chemotherapy’ and ‘surgery’ were identified by searching Pubmed and ScienceDirect between January 1st 2000 and September 30th 2010. Data Collection and analysis: The trials included used platinum-based chemotherapy and involved stage III/IV disease that underwent neoadjuvant chemotherapy followed by surgery. Prognostic variables were identified for analysis including number/type of chemotherapy, % stage IV disease, % maximal cytoreductive surgery and whether a lymphadenectomy was performed. The % bowel surgery and ultra-radical surgery was also analysed. Main Results: Twenty six trials were identified as suitable for analysis and included 3 non-randomised Phase II studies, 2 retrospective case-control studies, 17 from retrospective analysis and 1 RCT. A significant association between taxane use vs platinum only (p = 0.019), year of publication (p = 0.032), % maximal interval cytoreduction (p = 0.046) and median overall survival was identified. No significant survival benefit was demonstrated with number of chemotherapy cycles (p = 0.065), lymphadenectomy (p = 0.813) and % bowel surgery performed (p = 0.606). Conclusions: The addition of taxane and % maximal cytoreduction achieved is associated with improved overall survival. There is, however no evidence that lymphadenectomy, number of chemotherapy cycles or bowel surgery influences survival.

Cite this paper
nullFarquharson, M. and Siddiqui, N. (2011) Prognostic factors for survival after neoadjuvant chemotherapy for advanced ovarian cancer: meta-analysis. Open Journal of Obstetrics and Gynecology, 1, 71-83. doi: 10.4236/ojog.2011.13014.
[1]   Pomel, C., Barton, D.P.J., McNeish, I. and Shepherd, J. (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. An International Journal of Obstetrics and Gynaecology, 115, 808-810. doi:10.1111/j.1471-0528.2008.01692.x

[2]   Hariprasad, R., Kumar, L. and Kapoor, A. (2007) Neoadjuvant chemotherapy for advanced ovarian cancer-editorial. Indian Journal of Medical & Paediatric Oncology, 28, 4-5.

[3]   Scottish Intercollegiate Guidelines Network (SIGN) (2003) Epithelial ovarian cancer, Clinical Guideline 75.

[4]   Vergote, I., Trope, C.G. and Armant, F. (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England Journal of Medicine, 363, 943-953. doi:10.1056/NEJMoa0908806

[5]   Allen, D.G., Heintz, A.P. and Touw, F.W. (1995) A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. European Journal of Gynaecologic Oncology, 16, 349-356.

[6]   Morrison, J., Swanton, A., Collins, S. and Kehoe, S. (2007) Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews, 4, CD005343. doi:10.1002/14651858.CD005343.pub2

[7]   Venesmaa, P. and Ylikorkala, O. (1992) Morbidity and Mortality associated with primary and repeat operations for ovarian cancer. Obstetrics & Gynecology, 79, 168-172.

[8]   Gerestein, C.G., Damhuis, R.A., Burger, C.W. and Kooi, G.S. (2009) Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: A systematic review. Gynecologic Oncology, 114, 523-527. doi:10.1016/j.ygyno.2009.03.011

[9]   Aletti, G.D., Long, H.J., Podratz, K.C. and Cliby, W.A. (2007) Is time to chemotherapy a determinant of prognosis in advancedstage ovarian cancer? Gynecologic Oncology, 104, 212-216. doi:10.1016/j.ygyno.2006.07.045

[10]   Gadducci, A., Sartori, E., Landoni, F., et al. (2005) Relationship between time interval from primary surgery to the start of taxaneplus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: Results of a multicenter retrospective Italian study. Journal of Clinical Oncology, 23, 751-758. doi:10.1200/JCO.2005.03.065

[11]   Chan, Y.M., Ng, T.Y., Ngan, H.Y. and Wong, L.C. (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study. Gynecologic Oncology, 88, 9-16. doi:10.1006/gyno.2002.6849

[12]   Moher, D., Liberati, A., Tetzlaff, J. and Altman, D.G. (2009) PRISMA group. preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. British Medicine Journal, 339, b2535. doi:10.1136/bmj.b2535

[13]   Ansquer, Y., Leblanc, E., Clough, K., Morice, P., Dauplat, J., Mathevet, P., et al. (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer, 91, 2329-2334. doi:10.1002/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.0.CO;2-U

[14]   Kayikciog, F., Kose, M.F., Boran, N., Caliskan, E. and Tulunay, G. (2001) Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. International Journal of Gynecological Cancer, 11, 466-470. doi:10.1046/j.1525-1438.2001.01064.x

[15]   Kuhn, W., Rutke, S., Spathe, K., Schmalfeldt, B., Florack, G. and Von, H.B. (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIC ovarian carcinoma. Cancer, 92, 2585-2591. doi:10.1002/1097-0142(20011115)92:10<2585::AID-CNCR1611>3.0.CO;2-#

[16]   Vrscaj, M.U. and Rakar, S. (2002) Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: A retrospective case-control study. European Journal of Gynaecolocal Oncology, 23, 405-410.

[17]   Ushijima, K., Ota, S., Komai, K., Matsuo, G., Motoshima, S., Honda, S., et al. (2002) Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. International Surgery, 87, 185-190.

[18]   Morice, P., Dubernard, G., Rey, A., Atallah, D., Pautier, P., Pomel, C., et al. (2003) Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. Journal of the American Colloge of Surgeons, 197, 955-963. doi:10.1016/j.jamcollsurg.2003.06.004

[19]   Mazzeo, F., Berlière, M., Kerger, J., Squifflet, J., Duck, L., D’Hondt, V., et al. (2005) Neoadjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecolocal Oncology, 23, 7445-7453.

[20]   Fanfani, F., Ferrandina, G., Corrado, G., Fagotti, A., Zahut, H.V., Mancuso, S., et al. (2002) Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIC ovarian cancer patients. Oncology, 65, 316-322. doi:10.1159/000074644

[21]   Loizzi, V., Cormio, G., Rossi, C.A., Di, G.A.R., Cuccovillo, A. and Selvaggi, L. (2005) Neoadjuvant chemotherapy in advanced ovarian cancer: A case-control study. International Journal of Gynecological Cancer, 15, 217-223. doi:10.1111/j.1525-1438.2005.15206.x

[22]   Le, T., Faught, W., Hopkins, L. and Fung, M.F.K. (2005) Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. International Journal of Gynecological Cancer, 15, 770-775. doi:10.1111/j.1525-1438.2005.00134.x

[23]   Hegazy, M.A.F., Hegazi, R.A.F., Elshafei, M.A., Setit, A.E., Elshamy, M.R., Eltatoongy, M., et al. (2005) Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World Journal of Surgery Oncology, 3, 57-64. doi:10.1186/1477-7819-3-57

[24]   Avril, N., Sassen, S., Schmalfeldt, B., Naehrig, J., Rutke, S., Weber, W.A., et al. (2005) Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advancedstage ovarian cancer. Jouanl of Clinical Oncology, 23, 7445-7453. doi:10.1200/JCO.2005.06.965

[25]   Everett, E.N., French, A.E., Stone, R.L., Pastore, L.M., Jazaeri, A.A., Anderson, W.A., et al. (2006) Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. American Jouranl of Obstetrics and Gynecology, 195, 568-576. doi:10.1016/j.ajog.2006.03.075

[26]   Lee, S., Kim, B., Lee, J., Park, C., Lee, J. and Bae, D. (2006) Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. Journal of Obstetrics and Gynecology, 32, 99-106.

[27]   Inciura, A., Simavicius, A., Juozaityte, E., Kurtinaitis, J., Nadisauskiene, R., Svedas, E., et al. (2006) Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: A retrospective study of 574 patients. Biomed Central, 6, 153. doi:10.1186/1471-2407-6-153

[28]   Deo, S.V.S., Goyal, H., Shukla, N.K., Raina, V., Kumar, L., Srinivas, G., et al. (2006) Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Indian Journal of Cancer, 43, 117-121. doi:10.4103/0019-509X.27933

[29]   Le, T., Alshaikh, G., Hopkins, L., Faught, W. and Fung, M.F.K. (2006) Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Annuals of Surggical Oncology, 13, 1711-1716. doi:10.1245/s10434-006-9125-6

[30]   Hou, J.Y., Kelly, M.G., Yu, H., McAlpine, J.N., Azodi, M., Rutherford, T.J., et al. (2007) Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecological Oncology, 105, 211-217. doi:10.1016/j.ygyno.2006.11.025

[31]   Rafii, A., Deval, B., Geay, J.F., Chopin, N. and Paoletti, X., Paraiso, D., et al. (2007) Treatment of FIGO stage IV ovarian carcinoma: Results of primary surgery or interval surgery after neoadjuvant chemotherapy: A retrospective study. International Journal of Gynecological Cancer, 17, 777-783. doi:10.1111/j.1525-1438.2007.00905.x

[32]   Rosa, D.D., Ton, N.C., Clamp, A., Mullamitha, S., Lau, S., Clayton, R., et al. (2007) The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. Clinical Oncology, 19, 125-128. doi:10.1016/j.clon.2006.11.015

[33]   Ghaemmaghami, F., Karimi-Zarchi, M., Modares-Gilani, M., Mousavi, A. and Behtash, N. (2008) Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery. Asian Pacific Journal of Cancer Prevention, 9, 719-724.

[34]   Suprasert, P., Tiyanon, J. and Kietpeerakool, C. (2008) Outcome of interval debulking in advanced ovarian cancer patients. Asian Pacific Journal of Cancer Prevention, 9, 519-524.

[35]   P?lcher, M., Mahner, S., Ortmann, O., Hilfrich, J., Diedrich, K., Breitbach, G., et al. (2009) Neoadjuvant chemotherapy with docetaxel in advanced ovarian cancer—a prospective multicenter phase II trial (PRIM OVAR). Oncologu Reports, 22, 605-613.

[36]   Bilici, A., Salepci, T., Dane, F., Gumus, M., Ustaalioglu, B.B.O., Seker, M., et al. (2010) Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: A single centre experience. Archives of Gynecology and Obstetics, 282, 417-425. doi:10.1007/s00404-009-1330-7

[37]   Bristow, R.E. and Chi, D.S. (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytor-eduction for advanced ovarian cancer: A meta-analysis. Gynecological Oncology, 103, 1070-1076. doi:10.1016/j.ygyno.2006.06.025

[38]   Hoskins, W.J., Bundy, B.N., Thigpen, J.T. and Omura, G.A. (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A gynaecologic oncology group study. Gynecological Oncology, 47, 159-166. doi:10.1016/0090-8258(92)90100-W

[39]   Pecorelli, S., Odicino, F. and Favalli, G. (2002) Interval debulking surgery in advanced epithelial ovarian cancer. Best Practice and Research Clinical Obstetrics and Gynaecology, 16, 573-583. doi:10.1053/beog.2002.0302

[40]   Qayyum, A., Coakley, F.V., Westphalen, A.C., Hricak, H., Okuno, W.T. and Powell, B. (2005) Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecological Oncology, 96, 301-306. HHUdoi:10.1016/j.ygyno.2004.06.054

[41]   Panici, P.B., Maggioni, A., Hacker, N., Landoni, F., Acker-Mann, S., Campagnutta, E., et al. (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial. Journal of the National Cancer Institue, 97, 560-566. doi:10.1093/jnci/dji102

[42]   Eisenkop, S.M. and Spirtos, N.M. (2001) The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. Gynecological Oncology, 82, 143-149. doi:10.1006/gyno.2001.6232

[43]   Kim, H.S., Ju, W., Jee, B.C., Kim, Y.B., Park, N.H. and Song, Y.S. (2010) Systematic lymphadenectomy for survival in epithelial ovarian cancer: A meta-analysis. International Journal of Gynecological Cancer, 20, 520-528. doi:10.1111/IGC.0b013e3181d6de1d

[44]   National Institute for Health and Clinical Excellence (NICE) (2011) Ovarian cancer: Full guideline for prepublication check.